Cargando…
The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG
BACKGROUND: The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [(18)F]fluorodeoxyglucose (FDG), K(m). Among the shortcomings are tim...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175513/ https://www.ncbi.nlm.nih.gov/pubmed/24267032 http://dx.doi.org/10.1186/2191-219X-3-77 |
_version_ | 1782336497355063296 |
---|---|
author | van den Hoff, Jörg Oehme, Liane Schramm, Georg Maus, Jens Lougovski, Alexandr Petr, Jan Beuthien-Baumann, Bettina Hofheinz, Frank |
author_facet | van den Hoff, Jörg Oehme, Liane Schramm, Georg Maus, Jens Lougovski, Alexandr Petr, Jan Beuthien-Baumann, Bettina Hofheinz, Frank |
author_sort | van den Hoff, Jörg |
collection | PubMed |
description | BACKGROUND: The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [(18)F]fluorodeoxyglucose (FDG), K(m). Among the shortcomings are time dependence, susceptibility to errors in scanner and dose calibration, insufficient correlation between systemic distribution volume and body weight, and, consequentially, residual inter-study variability of the arterial input function (AIF) despite SUV normalization. Especially the latter turns out to be a crucial factor adversely affecting the correlation between SUV and K(m) and causing inter-study variations of tumor SUVs that do not reflect actual changes of the metabolic uptake rate. In this work, we propose to replace tumor SUV by the tumor-to-blood standard uptake ratio (SUR) in order to distinctly improve the linear correlation with K(m). METHODS: Assuming irreversible FDG kinetics, SUR can be expected to exhibit a much better linear correlation to K(m) than SUV. The theoretical derivation for this prediction is given and evaluated in a group of nine patients with liver metastases of colorectal cancer for which 15 fully dynamic investigations were available and K(m) could thus be derived from conventional Patlak analysis. RESULTS: For any fixed time point T at sufficiently late times post injection, the Patlak equation predicts a linear correlation between SUR and K(m) under the following assumptions: (1) approximate shape invariance (but arbitrary scale) of the AIF across scans/patients and (2) low variability of the apparent distribution volume V(r) (the intercept of the Patlak Plot). This prediction - and validity of the underlying assumptions - has been verified in the investigated patient group. Replacing tumor SUVs by SURs does improve the linear correlation of the respective parameter with K(m) from r = 0.61 to r = 0.98. CONCLUSIONS: SUR is an easily measurable parameter that is highly correlated to K(m). In this respect, it is clearly superior to SUV. Therefore, SUR should be seriously considered as a drop-in replacement for SUV-based approaches. |
format | Online Article Text |
id | pubmed-4175513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer |
record_format | MEDLINE/PubMed |
spelling | pubmed-41755132014-09-30 The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG van den Hoff, Jörg Oehme, Liane Schramm, Georg Maus, Jens Lougovski, Alexandr Petr, Jan Beuthien-Baumann, Bettina Hofheinz, Frank EJNMMI Res Original Research BACKGROUND: The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [(18)F]fluorodeoxyglucose (FDG), K(m). Among the shortcomings are time dependence, susceptibility to errors in scanner and dose calibration, insufficient correlation between systemic distribution volume and body weight, and, consequentially, residual inter-study variability of the arterial input function (AIF) despite SUV normalization. Especially the latter turns out to be a crucial factor adversely affecting the correlation between SUV and K(m) and causing inter-study variations of tumor SUVs that do not reflect actual changes of the metabolic uptake rate. In this work, we propose to replace tumor SUV by the tumor-to-blood standard uptake ratio (SUR) in order to distinctly improve the linear correlation with K(m). METHODS: Assuming irreversible FDG kinetics, SUR can be expected to exhibit a much better linear correlation to K(m) than SUV. The theoretical derivation for this prediction is given and evaluated in a group of nine patients with liver metastases of colorectal cancer for which 15 fully dynamic investigations were available and K(m) could thus be derived from conventional Patlak analysis. RESULTS: For any fixed time point T at sufficiently late times post injection, the Patlak equation predicts a linear correlation between SUR and K(m) under the following assumptions: (1) approximate shape invariance (but arbitrary scale) of the AIF across scans/patients and (2) low variability of the apparent distribution volume V(r) (the intercept of the Patlak Plot). This prediction - and validity of the underlying assumptions - has been verified in the investigated patient group. Replacing tumor SUVs by SURs does improve the linear correlation of the respective parameter with K(m) from r = 0.61 to r = 0.98. CONCLUSIONS: SUR is an easily measurable parameter that is highly correlated to K(m). In this respect, it is clearly superior to SUV. Therefore, SUR should be seriously considered as a drop-in replacement for SUV-based approaches. Springer 2013-11-23 /pmc/articles/PMC4175513/ /pubmed/24267032 http://dx.doi.org/10.1186/2191-219X-3-77 Text en Copyright © 2013 van den Hoff et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research van den Hoff, Jörg Oehme, Liane Schramm, Georg Maus, Jens Lougovski, Alexandr Petr, Jan Beuthien-Baumann, Bettina Hofheinz, Frank The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG |
title | The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG |
title_full | The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG |
title_fullStr | The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG |
title_full_unstemmed | The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG |
title_short | The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG |
title_sort | pet-derived tumor-to-blood standard uptake ratio (sur) is superior to tumor suv as a surrogate parameter of the metabolic rate of fdg |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175513/ https://www.ncbi.nlm.nih.gov/pubmed/24267032 http://dx.doi.org/10.1186/2191-219X-3-77 |
work_keys_str_mv | AT vandenhoffjorg thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT oehmeliane thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT schrammgeorg thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT mausjens thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT lougovskialexandr thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT petrjan thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT beuthienbaumannbettina thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT hofheinzfrank thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT vandenhoffjorg petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT oehmeliane petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT schrammgeorg petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT mausjens petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT lougovskialexandr petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT petrjan petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT beuthienbaumannbettina petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg AT hofheinzfrank petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg |